Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Anti-Infective Agents

Paclitaxel

Cyclophosphamide

Carboplatin

Bevacizumab

Doxorubicin

Liposomal doxorubicin

Albumin-Bound Paclitaxel

Lenograstim

Tubulin Modulators

Antimitotic Agents

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Eligible patients will receive:

* nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.
* Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.
* Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.

After completion of the above regimen, patients will receive:

* Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.
* Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.
* Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.

Patients will then proceed with:

- Surgery including axillary staging

A minimum of 4 weeks post operatively, patient will receive:

- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses.

Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim

Jasgit C. Sachdev, MD

The purpose of this study is to determine how well this combination of chemotherapy drugs works with bevacizumab in eliminating primary tumor in the breast prior to surgery(pathological complete response or pCR in the breast). Bevacizumab is a drug that works by blocking new blood vessel formation by the tumor cells. Giving chemotherapy and bevacizumab before surgery may allow for lesser amount of breast tissue to be removed. To be able to predict in the future which patients are more likely to get pCR to this drug combination, specialized tests on tumor tissue will be performed.

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer

National Comprehensive Cancer Network

Celgene Corporation

Genentech, Inc.

University of Tennessee Cancer Institute

Spots Global Cancer Trial Database for er, pr and her2 negative